KHABBARD Robert Dejl (US),ХАББАРД Роберт Дейл (US),MAKDENIEL Kit F. (US),МАКДЭНИЕЛ Кит Ф. (US),PARK Chang Khoon (US),ПАРК Чанг Хоон (US),PRATT Dzhon K. (US),ПРАТТ Джон К. (US),SOLTVEDEL Todd (US),СОЛТ,KHABBARD Robert Dejl,ХАББАРД Роберт Дейл,MAKDENIEL Kit F.,МАКДЭНИЕЛ Кит Ф.,PARK Chang Khoon,ПАРК Чанг Хоон,PRATT Dzhon K.,ПРАТТ Джон К.,SOLTVEDEL Todd,СОЛТВЕДЕЛ Тодд,SUN Chaokhun,СУНЬ Чаохун,VAN Le,ВА
申请号：
RU2014153628
公开号：
RU0002632915C2
申请日:
2012.06.12
申请国别(地区):
RU
年份:
2017
代理人:
摘要：
FIELD: pharmacology.SUBSTANCE: invention relates to a compound of formula (I) or its pharmaceutically acceptable salts: , wherein J is a group of formula IIa, R1a is C1-C3alkyl； Y1a is N or CRxa, where Rxa is H, X2a is selected from the group consisting of: H, C1-C4alkyl； X1a is selected from the group consisting of: hydrogen, halogen, C1-C6alkyl, C1-C4haloalkyl,-O-C1-C4alkyl, -O-C1-C3alkylene-C3-C7cycloalkyl, -O-C1-C4haloalkyl, -O-C1-C3alkylene(5-membered heterocycloalkyl having 1 heteroatom selected from O), -O-C1-C6alkylene-N(R10)2, -O-C1-C3alkylene-C(O)OC1-C4alkyl, -C2-C4alkenylene-C(O)-O-C1-C4alkyl, -C(O)-C1-C4alkyl, C(O)O-C1-C4alkyl, C(O)NR10R12, -NR10-C1-C3alkylene-C(O)-C1-C4alkyl, -SO2NR10R12 and any of the groups: ii) 6-membered heterocycloalkenyl, which may be substituted with 1 R2； iii) 5-6 membered heterocycloalkyl with 1 to 2 heteroatoms selected from N, which may be substituted with 1-2 R3； iv) 5-6 membered heteroaryl with 1-3 heteroatoms independently selected from N, O, 9-10 membered bicyclic heteroaryl with 1 to 3 heteroatoms independently selected from N, S, which may be substituted with 1-2 R4； v) phenyl which may be substituted with 1-2 R6； X3 is LG where L is absent or is selected from the group consisting of: -O-, -O-C1-C3alkylene； and G is selected from the group consisting of: phenyl, 6-membered heteroaryl with 1 heteroatom selected from N, 9-membered bicyclic heteroaryl with 2 heteroatoms, selected from N, C3-C7cycloalkyl, 6-membered heterocycloalkyl with 1 heteroatom selected from N, O, where G may be substituted with 1-2 groups, A2 is CR18, and A1, A3 and A4 are CR19, values of the remaining substituents are indicated in the claims. The invention also relates to individual compounds, to a pharmaceutical composition and to a method for cancer treatment.EFFECT: new compounds with proliferative activity are obtained.20 cl, 6 tbl, 293 exИзобретение относится к соединению формулы (I) или его фармацевтически приемлемым солям:,в которой J предст
